Riskpilot← Back to searchSign inGet full accessAbera Bioscience AB
ABActiveOrg 5569090904Virdings Allé 32Research and experimental development on natural sciences and engineering · NACE 7210Est. 20125-9 employees
Revenue 2024
SEK 0
EBITDA margin
—
+94% vs 2023
Equity ratio
63.6%
Financial strength
Net profit 2024
SEK -1,1M
+93% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -1,1M | +94% |
| Net profit | SEK -1,1M | +93% |
| Total assets | SEK 13,6M | +46% |
| Equity | SEK 8,7M | +53% |
| Employees | — | — |
Legal name
Abera Bioscience AB
Org number
5569090904
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
3 november 2012
Share capital
SEK 1 228 000
Employees
5-9
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas ensam av Alriksson, Maria Ulrika Elisabet
Company purpose
Föremålet för bolagets verksamhet är att bedriva natur- vetenskaplig forskning och utveckling samt därmed förenlig verksamhet.
Address
Virdings Allé 32
Email
info@aberabio.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 529 | −1 187 | −2 274 | −2 274 | −2 471 | −3 642 | −9 164 | −19 393 | −16 799 | −1 058 |
| Depreciation & amort. | −52 | −31 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −62 |
| EBIT | 477 | −1 218 | −2 274 | −2 274 | −2 471 | −3 642 | −9 164 | −19 393 | −16 799 | −1 120 |
| Net financials | — | — | — | — | — | — | −1 | 13 | 82 | 22 |
| Profit before tax | 477 | −1 218 | −2 274 | −2 274 | −2 471 | −3 642 | −9 165 | −19 380 | −16 717 | −1 099 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 477 | −1 218 | −2 274 | −2 274 | −2 471 | −3 642 | −9 165 | −19 380 | −16 717 | −1 099 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 6 343 | 6 774 | 3 958 | 2 421 | 4 887 | 2 966 | 31 374 | 19 574 | 9 350 | 13 607 |
| Equity | 5 932 | 6 239 | 3 031 | 757 | 4 071 | 428 | 29 152 | 16 779 | 5 658 | 8 659 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 411 | 535 | 926 | 1 664 | 816 | 2 537 | 2 221 | 2 795 | 3 692 | 4 947 |
| Total debt | 411 | 535 | 926 | 1 664 | 816 | 2 537 | 2 221 | 2 795 | 3 692 | 4 947 |
EBITDA margin
-105800000.0%
This company
15.8%
Market median
-669620353% vs market
20152024
Equity ratio
63.6%
This company
38.2%
Market median
+66% vs market
20152024
Return on equity
-12.7%
This company
18.4%
Market median
-169% vs market
20152024
Net profit margin
-109900000.0%
This company
8.1%
Market median
-1356790223% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
0.57×
This company
0.62×
Market median
+8% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BM Audit | Audit | 2020 | — | — |
MU Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Abera Bioscience AB 
Pneubera ABBoard members of Abera Bioscience AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bo Magnus Lagerberg | Audit | 0 companies |
| Maria Ulrika Elisabet Alriksson | Chief Executive Officer | 0 companies |
| Harry Mikael Råstedt | Board of Directors | 0 companies |
| Alf Erik Anton Lindberg | Board of Directors | 0 companies |
| Sjouke Luirink | Board of Directors | 0 companies |
| Hans Fredrik Juserius | Board of Directors | 0 companies |
| Florence Louise Isabelle Marie Vicaire | Board of Directors | 0 companies |
| Sohila Zadran | Board of Directors | 0 companies |
| Ulla Cristina Glad | Board of Directors | 0 companies |
| Leif Anders Gunnar Ericsson | Chairman | 0 companies |